Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab open-label pediatric pharmacokinetic and safety study in enthesitis-related arthritis and juvenile psoriatic arthritis
2023-508845-41-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label trial of bimekizumab in juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), juvenile psoriatic arthritis (JPsA) and juvenile ankylosing spondylitis (JAS), sponsored by UCB. Primary endpoint: Plasma bimekizumab concentrations. Planned start Mar 2025; status: authorised.
02
Drugs
bimekizumab
03
Conditions
juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)juvenile psoriatic arthritis (JPsA)juvenile ankylosing spondylitis (JAS)
Beyond the preview
Go deeper on 2023-508845-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508845-41-00.